Shots:
- Regeneron pauses dosing of the garetosmab (REGN2477) in the ongoing P-II LUMINA-1 study in patients with FOP. The pause is due to fatal serious AEs in the study during the open-label extension during which all patients received active treatment
- Regeneron shared the update with the trial’s IDMC and regulatory authorities and will conduct a review of the study to better understand the benefit/risk profile of garetosmab in people with FOP
- Garetosmab is a VelocImmune-derived mAb that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP
Click here to read the full press release/ article | Ref: Regeneron | Image: The Print
The post Regeneron Pauses Dosing of Garetosmab (REGN2477) in P-II LUMINA-1 Study for Fibrodysplasia Ossificans Progressiva first appeared on PharmaShots.
